A prospective, randomized controlled trial comparing alendronate and alendronate plus alphacalcidol therapy in patients with steroid-induced osteoporosis accompanied with interstitial pneumonias
Not Applicable
- Conditions
- interstitial pneumonias
- Registration Number
- JPRN-UMIN000004188
- Lead Sponsor
- agasaki University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(1) The patients who have severe complications (2) The patients who have the diseases of bone metabolism (3) The patients who were administered steroid therapy within a year (4) The patients who are administered therapy affecting bone metabolism (5) The patients who have fracture or scoliosis at 3rd to 5th lumbar (6) The patients who have impaired renal function (Cr > 1.5mg/dl) (7) The patients who are contraindicated to take alendronate or alphacalcidol (8) The patients who are pregnant (9) The patients who attended clinical trials within three months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1) The change in the lumbar-spine bone mineral density from baseline (2) The change in the markers of of bone metabolism from baseline
- Secondary Outcome Measures
Name Time Method